Frontline Nilotinib in Pediatric Chronic Myeloid Leukemia: An Interim Analysis of SCCCG[PLUS]-CML 2023
Year: 2026
Type: article
Abstract: Background: Evidence on the depth of molecular response and long-term tolerability of frontline nilotinib in pediatric chronic myeloid leukemia in chronic phase (CML-CP) remains limited. Methods: Children with newly diagnosed BCR::ABL1-positive CML-CP received nilotinib 230 mg/m2 twice daily in a prospective multicenter cohort. BCR::ABL1 on the International Scale (IS) was assessed at scheduled visits; major molecular response (MMR), MR4, and MR4.5 were summarized among patients with data at cycles 3, 6, and 12. Adverse events were graded using Common Terminology Criteria for Adverse Events version 5.0. Nilotinib trough concentrations were assessed in 54 patients using morning predose blood samples analyzed at a specialized third-party clinical laboratory. Results: Ninety-two children were included (median age, 10.3 years [IQR, 7.6–12.5]); 64 (69.6%) were male. MMR was recorded in 22/78 (28.2%), 37/64 (57.8%), and 40/50 (80.0%) evaluable patients at cycles 3, 6, and 12, respectively. At cycle 12, 19/50 (38.0%) had MR4 and 15/50 (30.0%) had MR4.5. At a median follow-up of 1.79 years (IQR, 1.09–2.83), the estimated 2-year event-free survival was 96.4% (95% CI, 86.1–99.1%). Common adverse events included ALT elevation (60/90, 66.7%), myelosuppression (43/87, 49.4%), hyperbilirubinemia (35/89, 39.3%), and rash (29/92, 31.5%). At cycle 6, nilotinib trough concentration showed a modest inverse correlation with BCR::ABL1 transcript levels (Spearman ρ = −0.329, p = 0.044). Conclusions: Frontline nilotinib produced clinically meaningful molecular responses in evaluable pediatric patients with CML-CP. The observed association between trough concentration and molecular response was modest and exploratory and requires prospective validation.
Source: Biomedicines
Authors: Zhong Fan, Hui-Rong Mai, Xiu-Ya Huang, Li-Hua Yang, Fei He, Liu-Hua Liao, Xing-Jiang Long, Qi-Wen Chen, Qiao-Ru Li, Dun-Hua Zhou, Wei-Na Zhang, Li-Li Liu, Bi-Yun Guo, Hai-Xia Guo, Xiao-Yan Yang, Hui-Qin Chen, Min-Hui Zeng, Wu-Qing Wan, Hong-Ying Wei, Ya-Wei Zou, He-Kui Lan, Wen-Jie Xiong, Hao-Yan Ren, Xiao-Bo Zhou, Li-Min Lin, Xin Tian, Cong Liang, Xue-Qun Luo, Li-Bin Huang, Qiang Fu, Xiao-Li Zhang
Institutions: Sun Yat-sen University, The First Affiliated Hospital, Sun Yat-sen University, Shenzhen Children's Hospital, Zhujiang Hospital, Southern Medical University, Jiangxi Provincial Children's Hospital, Huizhou Central People's Hospital, Liuzhou General Hospital, First Affiliated Hospital of Nanchang University, Zhongshan People's Hospital, Sun Yat-sen Memorial Hospital, Guangzhou Women and Children Medical Center, Guangzhou Medical University, Guangdong Medical College, First Affiliated Hospital of Xiamen University, Nanfang Hospital, Affiliated Hospital of Guizhou Medical University, Third Affiliated Hospital of Sun Yat-sen University, Hunan Provincial People's Hospital, Second Xiangya Hospital of Central South University, Guangxi Medical University, First Affiliated Hospital of Guangzhou Medical University, Second Affiliated Hospital of Shantou University Medical College, Kunming Children's Hospital, Wuhan Children's Hospital, Huazhong University of Science and Technology
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,137
OpenAlex ID: W7234513760
